Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PET/MRI Clear all
Completed No phase listed Observational

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

NCT04409314
View directory record Official record
Conditions
Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Malignant Neoplasm, Recurrent Plasma Cell Myeloma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Malignant Neoplasm, Refractory Plasma Cell Myeloma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Interventions
Fluorine F 18-fluoroazomycin Arabinoside, Positron Emission Tomography
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 20, 2026, 1:54 AM EDT
Withdrawn Not applicable Interventional

The Brain Ketone Body Challenge Imaging Study

NCT03204604
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Challenge A - low calorie Ensure®, Challenge B - Ensure® plus ketone esters (KE), PET Scan, Cognitive Testing - FCSRT, Story Recall, BVRT, CogState One Card Learning
Dietary Supplement · Procedure · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 20, 2026, 1:54 AM EDT
Completed Early Phase 1 Interventional

PET/MRI Evaluation of Cardiac Amyloid

NCT03119558
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
18F-Florbetaben (Neuraceq®) PET/MRI
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Sep 20, 2026, 1:54 AM EDT
Terminated Phase 1 Interventional Results available

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

NCT04933617
View directory record Official record
Conditions
Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)
Interventions
Rituximab, Etoposide, Copanlisib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, ECHO, EKG, MRI Brain, 18F-FDG - PET, CT Scan, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture (LP)
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 20, 2026, 1:54 AM EDT
Active, not recruiting Not applicable Interventional

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

NCT02194738
View directory record Official record
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1655
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 20, 2026, 1:54 AM EDT
Suspended Phase 1 Interventional

Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma

NCT04309552
View directory record Official record
Conditions
Glioma
Interventions
18F-FMISO PET, 18F-FLT PET
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 20, 2026, 1:54 AM EDT
Not listed Phase 2 Interventional

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

NCT00083083
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, etoposide, paclitaxel, vinblastine sulfate, vinorelbine tartrate, gene expression analysis, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Drug · Genetic · Procedure + 1 more
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 20, 2026, 1:54 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

NCT05996523
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma (SCC)
Interventions
PRGN-2009, Pembrolizumab, EKG, CT, PET scan, MRI, Biopsy
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 20, 2026, 1:54 AM EDT
Recruiting Phase 1Phase 2 Interventional

Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

NCT01542879
View directory record Official record
Conditions
Cancer
Interventions
WB-DW-MR scan, 18-F-FDG PET scan, Ferumoxytol, 18-F-FDG PET/MR scan
Procedure · Drug
Lead sponsor
Heike E Daldrup-Link
Other
Eligibility
6 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 20, 2026, 1:54 AM EDT
Active, not recruiting Phase 2 Interventional

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT04883242
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Isatuximab, Pomalidomide, Bone Marrow Biopsy, Bone Marrow Aspiration, Skeletal Survey X-Ray, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 20, 2026, 1:54 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

NCT04609046
View directory record Official record
Conditions
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Interventions
Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Lenalidomide, Lumbar Puncture, Magnetic Resonance Imaging, Methotrexate, Nivolumab, Positron Emission Tomography, Rituximab, Ultrasound Imaging
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
56
States / cities
Los Angeles, California • San Francisco, California • Coral Gables, Florida + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 20, 2026, 1:54 AM EDT
Recruiting Early Phase 1 Interventional

Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma

NCT05632562
View directory record Official record
Conditions
High Grade Glioma
Interventions
O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
10 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 20, 2026, 1:54 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Dynamic Connectivity Under Metabolic Constraints

NCT04106882
View directory record Official record
Conditions
Insulin Resistance, Healthy, Diet Modification, Aging
Interventions
Ketones, Glucose
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 79 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Charlestown, Massachusetts • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Sep 20, 2026, 1:54 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

NCT04508088
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn Disease
Interventions
Coronal T1 weighted spin echo images, Spin-lattice relaxation (T1), Magnetic resonance spectroscopy, Blood Draw
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 20 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 20, 2026, 1:54 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Novel Positron Emission Tomography (PET) Radiotracer to Image Phosphodiesterase-4B (PDE4B)

NCT03030391
View directory record Official record
Conditions
Healthy
Interventions
PET, MRI
Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 20, 2026, 1:54 AM EDT
Not listed Phase 2 Interventional

An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation

NCT01260480
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms
Interventions
[18F]-ML-10 in conjunction with PET imaging
Other
Lead sponsor
Aposense Ltd.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
4
States / cities
Boston, Massachusetts • Teaneck, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2010 · Synced Sep 20, 2026, 1:54 AM EDT
Completed Phase 1 Interventional

PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis

NCT02417688
View directory record Official record
Conditions
Carotid Atherosclerosis
Interventions
Cu[64]-25%-CANF-Comb PET-MR
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Sep 20, 2026, 1:54 AM EDT
Recruiting Phase 2 Interventional

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

NCT07078604
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Chemotherapy, Computed Tomography, Sargramostim, Biospecimen Collection, Positron Emission Tomography (PET), Image Guided Biopsy
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 20, 2026, 1:54 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)

NCT03702816
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Inflammation
Interventions
GE180 PET Scan
Drug
Lead sponsor
Aaron Ritter, MD
Other
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 20, 2026, 1:54 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

NCT07275216
View directory record Official record
Conditions
Classic Hodgkin Lymphoma
Interventions
Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Echocardiography Test, Gemcitabine, Pembrolizumab, Physical Performance Testing, Positron Emission Tomography, Pulmonary Function Test
Procedure · Drug · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 20, 2026, 1:54 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

NCT05063552
View directory record Official record
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
172
States / cities
Little Rock, Arkansas • Dublin, California • Emeryville, California + 135 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 20, 2026, 1:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder

NCT01681849
View directory record Official record
Conditions
PTSD
Interventions
Placebo, Paroxetine, Positron Emission Tomography (PET) Imaging
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Sep 20, 2026, 1:54 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

PPG Project 3 - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients

NCT03279393
View directory record Official record
Conditions
PTSD, Trauma, Healthy
Interventions
fluorodeoxyglucose (FDG)-PET/MRI
Drug
Lead sponsor
Zahi Fayad
Other
Eligibility
30 Years to 65 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 20, 2026, 1:54 AM EDT
Active, not recruiting Not applicable Interventional Results available

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

NCT02293954
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastrointestinal Cancer, Liver and Intrahepatic Biliary Tract Cancer, Lung Cancer, Metastatic Cancer, Pancreatic Cancer, Rectal Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
radionuclide imaging, positron emission tomography, laboratory biomarker analysis, pharmacological study, Cu 64 anti-CEA monoclonal antibody M5A IV
Procedure · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 20, 2026, 1:54 AM EDT